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ygen was not specifically reported in our series; however,
the CTCAE defines grade 2 hypoxia as the need for inter-
mittent oxygen and grade 3 as the need for continuous ox-
ygen. Seven patients became oxygen dependent after
treatment (at 30 days); however, by 3 months none of these
patients were dependent on oxygen.
More recently, the Radiation Therapy and Oncology
group17 completed a phase II study of SBRT in high-risk pa-
tients. Grade 3 and 4 protocol-specific toxicities were re-
ported in 7 of 55 patients (12.7%) and 2 of 55 (3.6%),
respectively. All but 1 of these (8/55, 14.5%) of these tox-
icities were respiratory associated. In our series, 21 of 148
patients (14.2%) had perioperative grade 3 or 4 respiratory
complications, suggesting that even in a compromised pa-
tient population resection can be undertaken with similar
outcomes to SBRT. Currently, the American College of
Surgeons and the Radiation Therapy and Oncology Group
are developing a randomized study to compare SR and
SBRT in high-risk patients with lung cancer. Treatment-
related toxicity and effects on pulmonary function will be
key end points in this study.
In conclusion, in this randomized study of a patient co-
hort with stage I NSCLC at greater than average risk for lo-
bectomy, brachytherapy had no significant effect on lung
function at short-term follow-up. FEV1% and DLCO%
were equally preserved in both groups. The 30-day inci-
dences of grade 3 and 4 respiratory complications in the
SR and SRB arms were not significantly different.
Follow-up, including recording of pulmonary function, is
ongoing at the 12- and 24- month time points to ascertain
the long-term impact of brachytherapy on lung function.
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Dr Walter Weder (Zurich, Switzerland). Fernando and col-
leagues are to be congratulated for having initiated and now fin-
ished a prospective, multicenter, randomized trial evaluating an
important oncologic question. Today they report on a secondary
study end point, lung function and dyspnea. Dr Fernando, congrat-
ulations on your clear presentation and thanks for sending me the
manuscript long before the meeting. I have 3 questions. In your ar-
ticle, you discussed the Lung Cancer Study Group Trial, which
evaluated lobectomy versus sublobar resection and you com-
mented as follows about pulmonary function tests, ‘‘However,
values were only obtained for 60% of eligible patients who had
at least 9-month follow-up.’’ My comment on your study is the
same. Unfortunately, for only two thirds of the patients were the
pulmonary function test values available at 3 months, and for
less than half at 12 months. Why didn’t you wait a few more
months with your analysis and publication? This would have im-
proved the value of this report significantly.
I will continue with my second question. The patients you in-
cluded had either low forced expiratory volume in 1 second or
low diffusing capacity of the lung for carbon monoxide. I assume
this is typically the patient with emphysema. You also included,
however, patients with either high pulmonary artery pressure or
impaired left ventricular function, and the pulmonary function
test values in these patients were normal. So these are completely
different disease categories. My question is, why didn’t youery c September 2011
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Sanalyze these 2 groups of patients separately? I assume that any ef-
fect of brachytherapy on lung function could vary by disease cat-
egory. Finally, in your manuscript you mentioned that
endobrachytherapy delivers 100 Gy. What is the depth of the radi-
ation field of this locally applied radiation therapy?
Dr Fernando. Thank you very much. Those are great questions,
and I appreciate the challenge. I think that you picked up a major
point. We only have the 3-month data in detail. We debated how
much we should put into the discussion of 12-month data that
we had available. We decided that we could report what we have
at the moment, but as we get the longer and more complete
follow-up, we recognize that 12-month data results may change.
Analyzing the 12-month data is important, because radiation pneu-
monitis can be seen up to 6 months afterward. Currently, we don’t
see a difference at 12 months; however, that may change, and that
will be reported in detail when available.
In terms of analyzing the groups you mention separately, that’s
a good question. We didn’t—
DrWeder. Can I interrupt briefly? So what, then, is the value of
the current analysis? You said that the major impact of radiation
pneumonitis is at 3 to 6 months. If you are not waiting that time,
we get the report that tells us, ‘‘Yes, it may not have an impact,
but we are not really sure.’’ If you would have waited another 6
months, we would have the relevant information.
Dr Fernando.Well, the 12-month data would help answer the
question specifically about radiation pneumonitis, but not about
other pulmonary complications, which typically you can see in
the perioperative period up to 30 days. So I think that the 30-day in-
formation is still important. In previous studies, radiation pneumo-
nitis has not really been reported with brachytherapy, although that
is one of the things about which people remain concerned. We are
taking a patient population at greater than average risk, we’re sutur-
ing on the lung, we’re not using Peri-Strips, for instance, to buttress
the repair. Other surgeons are concerned about the risk of things
like prolonged air leaks, pneumonia, and even empyemas. We
didn’t see any empyemas in this group. So I think the longer fol-
low-up will really address the issue of radiation pneumonitis in
its own right, and hopefullywe can answer that question better then.
In terms of the second question, why we didn’t analyze the
groups separately, the data that we have on the data sheets that
the various site clinical research associates sent to us did not spe-
cifically separate out those groups. I think that’s a very interesting
question. We do have access to the source documents (the pulmo-
nary function test values), and so perhaps we will have to go back
and analyze that information, so that we can try and separate those
patients into those who maybe have more restrictive disease rather
than emphysema. I think that’s an excellent question, and some-
thing that we should address.
Can you remind me of the third question?
DrWeder.You mention in the manuscript that a 100-Gy dose is
delivered but say nothing about the depth of the radiation. Is it
a few millimeters, or more?
Dr Fernando. It’s about 5 to 7 mm or up to 1 cm, depending on
how strong those radiation seeds are. So, in effect, whatwe’re doing
is improving our margins. I’m not sure which patients this benefits,
but I suspect that the patients who will benefit are those patients
who have closewedge resections or closemarginwedge resections.
If you do a wedge resection with a 1-cmmargin or a margin at leastThe Journal of Thoracic and Cathe diameter of the tumor, or you do a good segmental resection,
probably the brachytherapy will not be as helpful.
Dr Weder. Thank you.
Dr Scott J. Swanson (Boston, Mass). Excellent paper. I thought
it was really useful to hear that information at this point. Did your
teams learn anything about how to put these seeds in, such that it
got easier over the course of the trial? Can you share any of that
technical information? Second, pertaining to that last point, can
you share any information about margins? Did you measure
margins? Do you have any data about margins?
Dr Fernando. I’ll take the margin question first. I’ve gone
through the reviews that I’ve done thus far. One of the secondary
end points we had was to look at staple-line cytology. There are
some Japanese data, I think by Sawabata, where he swiped the
specimen on a glass slide and found differences between the
staple-line cytology and the actual histology. He even identified
patients who had positive staple-line cytology yet negative histol-
ogy. So we put that in as a secondary end point that we’re measur-
ing, and those data will eventually be presented. But what’s
interesting, as I read through the reports, is that people are actually
getting reads from their cytologists in there and they are going
back and taking bigger and bigger margins. So I think as a group,
the surgeons are actually doing better wedge resections or better
segments than maybe in previous studies. So far I have not seen
lot of local recurrences in the cases that I’ve analyzed.
The second thing, in terms of what have I learned, in terms of
a thoracoscopic approach, I personally like to use the Endo-Stitch
a lot, and I found with some of the Vicryl meshes that we have that
the Endo-Stitch does not sew very well through the mesh, and the
needle tends to get stuck. It’s a blunter needle. So I changed to us-
ing a standard needle, and what I do is I place the stitch through the
mesh and then into the lung, bring it up, and I have 2 long strands
of suture. Rather than trying to do an endoscopic tie, what I do is I
simply put a series of clips along the suture. So the clips serve as
my tie on the suture, and that also avoids having to actually do an
intracorporeal knot in the patient.
Dr Nasser K. Altorki (New York, NY). I enjoyed your presen-
tation. I want to agree a little bit with you and a little bit with
Walter. He made his point, but I think that there is a real issue of
delivering 100 Gy to a fresh suture line, and I think all of us
who do this worry about the issues that you described. I think in
that sense your report is helpful. Can you share with us issues
that relate to radiation exposure in the operating room? What do
you do? What is the risk to people in the room? You sew it. Do
you wear radioprotective gloves? Do you wear a shield?
Dr Robert J. Cerfolio (Birmingham, Ala). And any surgical
team members who might be pregnant in the operating room,
which is an issue.
Dr Fernando. That issue of radiation safety has been reported
in another article, with data not from this study but from a previous
single-center study (Smith RP, Schuchert M, Komanduri K,
Burton S, Heron DE, Luketich JD, et al. Dosimetric evaluation
of radiation exposure during I-125 vicryl mesh implants: implica-
tions for ACOSOG z4032. Ann Surg Oncol. 2007;14:3610-3). You
have to follow the regulations in place in your own hospital and
within your own state. I wear a lead apron when I do this. I try
not to handle the seeds directly, for instance not tying right
down into the knot with my fingers. When the implant is prepared,rdiovascular Surgery c Volume 142, Number 3 561
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Swhat you do is basically to place all the sutures in place into the
mesh with a lead shield over the active radiation seeds, and then
when you’re ready, you have all 4 sutures with the seeds into
the mesh. You pull each suture through, so that you are minimiz-
ing radiation exposure. The radiation physicist is in the room mea-
suring the radiation in the room and around the room. In terms of
actual safety for the patient, it’s really very safe. It’s a low dose
rate brachytherapy. And the falloff is rapid as you move away
from the source. In the study I just mentioned, dosimeters placed
on the patient’s shoulder measured very low doses of radiation in
these patients who had an implant placed. So it’s actually a low
dose of radiation exposure.
Dr Altorki. There is a glove that is lead impregnated that you
could use.562 The Journal of Thoracic and Cardiovascular SurgDr Daniel L. Miller (Atlanta, Ga). With regard to placement,
what we at Emory and some other surgeons throughout the United
States have been using is the pericardial Veritas strip, which is a lit-
tle bit wider. They have a wider version, and it’s very easy to han-
dle. You bring the suture out, and you clip the radiation seed suture
onto the buttress material. So you have no extra holes into the lung.
When you have expansion of the lung, there’s no tearing and so
forth. It really minimizes the amount of time spent handling the
radiation, and you’re not suturing into the lung in a way that
may produce prolonged air leaks and so forth. I know that wasn’t
allowed in this portion of the study, it’s off-study; however, I think
that in the future this is another way to look at that, to minimize
other lung problems and so forth.
Dr Fernando. Thank you.ery c September 2011
